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Vascular calciﬁcation is a common con-
sequence of aging, hypercholesterol-
emia, chronic renal insufﬁciency, and
diabetes (1). Stiffening of the large ar-
teries is a result of vascular calciﬁcation.
Carotid–femoral pulse wave velocity
(cfPWV) is considered the gold standard
measure of arterial stiffness (2) and has
been shown to be a strong predictor of
mortality and cardiovascular outcome.
We evaluated the association be-
tween arterial stiffness (evaluated by
cfPWV) and bone mass density (evalu-
ated with dual-energy X-ray absorpti-
ometry at the femoral neck), as well
as a comprehensive panel of bone
markers, in a well-characterized cohort
of 347 persons with type 1 diabetes. We
hypothesized that vascular calciﬁcation
is linked to decalciﬁcation of the bones.
The participants were recruited from
the outpatient clinic at Steno Diabetes
Center, Gentofte, Denmark. Written in-
formed patient consent and ethical
approval of the study were obtained.
A total of 164 (47%) participants were
women, mean6 SD age was 55.86 9.6
years and cfPWV was 11.0 6 3.4 m/s,
and median (interquartile range) para-
thyroid hormone (PTH) was 39.1 (29.1,
57.3) pg/mL.
Table 1 shows the unadjusted
and stepwise adjusted associations
between cfPWV and bone mineral
density, clinical bone markers (PTH,
25-hydroxyvitamin D, calcium, and phos-
phorus), and markers of bone min-
eral metabolism (endostatin, sclerostin,
Dickkopf 1, and osteoprotegerin). In un-
adjusted analyses, bone mineral density,
all clinical bone markers, and markers of
mineral metabolismdexcept calcium,
phosphorus, and Dickkopf 1dwere asso-
ciated with cfPWV (P # 0.041). After ad-
justment for age, sex, and mean arterial
pressure, the level of bone mineral den-
sity, PTH, and sclerostin remained associ-
ated with cfPWV (P # 0.027). After
adjustment for additional risk factors
(HbA1c, total cholesterol, BMI, antihyper-
tensive treatment, urinary albumin ex-
cretion rate, estimated glomerular
ﬁltration rate, and smoking), PTH re-
mained positively associated with
cfPWV (P = 0.014).
In the search for a link between bone
and vascular disease, we demonstrated
an association between arterial stiffness
and bone mineral density, clinical bone
markers, and markers of mineral metab-
olism. These associations lost signiﬁcance
after comprehensive adjustment, except
for the relationship between higher PTH
and increased arterial stiffness.
PTH is one of the main regulators of
calcium homeostasis. Secretion of PTH
from the parathyroid gland is triggered
by low serum calcium. PTH secretion re-
sults in raised serum calcium through its
release from the bones, reduced renal
excretion, and increased small intestine
absorption (3). Aside from its well-
established role in calcium homeostasis,
elevated PTH has been linked to pres-
ence of hypertension and cardiac hy-
pertrophy (4), and PTH excess may be
related to development of cardiovascu-
lar disease (5).
Our study consisted of a well-
characterized group of persons with
type 1 diabetes. Arterial stiffness was
evaluated using the gold standard
method, analyzed as a continuous vari-
able and with proper adjustment. Bone
mineral density was evaluated with ro-
bust methods, and all bone markers
were analyzed as continuous variables;
no arbitrary cutoffs were applied.
Our ﬁndings highlight PTH as a poten-
tial mediator for the cross talk between
bone and vascular disease. However,
our ﬁndings need validation, and pro-
spective studies investigating the
relationship between PTH and cardio-
vascular outcome in type 1 diabetes
are warranted. Depending on the results
of such studies, therapies known to re-
duce PTH (e.g., cinacalcet) could poten-
tially reduce the cardiovascular risk in
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vated PTH.
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Table 1—Unadjusted and stepwise-adjusted associations between cfPWV and measures of bone/mineral metabolism
Unadjusted
Adjusted for age, sex,
and mean arterial pressure
Adjusted for age, sex, mean
arterial pressure, and other risk factors
b P b P b P
Bone mineral density
Femoral neck bone mineral density 20.23 ,0.001 20.15 0.027 20.06 0.43
Clinical bone markers
PTH* 0.23 ,0.001 0.28 ,0.001 0.17 0.014
25-Hydroxyvitamin D 0.12 0.041 20.12 0.09 20.10 0.17
Ionized calcium 20.01 0.08 20.06 0.37 20.02 0.77
Phosphorus 0.07 0.19 0.11 0.13 0.001 0.98
Markers of bone mineral metabolism
Endostatin* 0.16 0.003 0.12 0.09 0.05 0.49
Sclerostin* 0.14 0.011 0.16 0.022 0.01 0.85
Dickkopf 1* 0.007 0.90 0.06 0.43 0.12 0.15
Osteoprotegerin* 0.36 ,0.001 0.13 0.08 0.02 0.77
Other risk factors included HbA1c, total cholesterol, BMI, antihypertensive treatment, urinary albumin excretion rate, estimated glomerular ﬁltration
rate, and smoking. cfPWV was measured with the SphygmoCor (AtCor Medical, Sydney, Australia). Plasma vitamin D [25(OH)D3] levels were
determined by high-performance liquid chromatography–tandem mass spectrometry. Plasma PTH levels were analyzed using a second-generation
electrochemiluminescence immunoassay (Cobas e601, Roche Diagnostics). Serum endostatin, sclerostin, Dickkopf 1, and osteoprotegerin were
measured by sandwich ELISA (Biomedica Medizinprodukte, Austria). *Log2 transformed for analyses. The b estimates represent standardized effect.
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